A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia

Inclusion Criteria: * Subjects aged ≥18 years * Diagnosed with solid tumor * On active chemotherapy with combined regimen * A baseline platelet count of \<75,000/μL within 2 days of screening * Hb ≧ 9.0 g/dL * ANC ≧ 1,500/uL * GOT and GPT ≤ 3 x ULN * Serum bilirubin ≤ 1.5 x ULN * Albumin ≥ 2.5 g/dL * Adequate renal function for chemotherapy: serum creatinine ≤ 1.5 × ULN (CTCAE Grade 1). * Be able to take oral medicine * ECOG performance ≤ 2 * Has a negative urine or serum pregnancy test at screening and is willing to use contraceptive measures during medication of this trial (Non-childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, tubal ligation and post-menopausal status) for patients with childbearing potential * Ability to participate and willingness to give written informed consent and to comply with the study restrictions Exclusion Criteria: * Single agent chemotherapy or not having chemotherapy * Serious cardiac, cerebrovascular, or pulmonary disease that, in the opinion of the investigator, would preclude trial medication * Severe GI tract obstruction that require continuous NG decompression * Subjects with hemoglobinopathies, e.g. sickle cell anaemia, thalassemia major * Any prior history of arterial or venous thrombosis * Any disease condition associated with active bleeding or requiring anticoagulation, heparin or warfarin * Pre-existing cardiac disease (congestive heart failure New York Heart Association (NYHA) G…